Patricklin at 03:21, 1 October 2023

2023-10-01T03:21:13Z

← Older revision		Revision as of 03:21, 1 October 2023
Line 49:		Line 49:
	==Mechanism of Action==		==Mechanism of Action==
	*α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See [[Tamsulosin]])		*α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See [[Tamsulosin]])
	*Theoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension ~~(and treats hypertension better as well)~~		*Theoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension
	**In a single-center European RCT, terazosin appears to be associated with a higher rate of symptomatic orthostatic hypotension<ref>de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33(5):481-8. doi: 10.1159/000019639. PMID: 9643668.</ref>		**In a single-center European RCT, terazosin (vs tamsulosin) appears to be associated with a higher rate of symptomatic orthostatic hypotension<ref>de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33(5):481-8. doi: 10.1159/000019639. PMID: 9643668.</ref>
	**In a meta-analysis from a Chinese team, more subjects receiving terazosin experienced dizziness and hypotension<ref>Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009 Aug;55(4):129-36. doi: 10.3109/19396360902833235. PMID: 19886768.</ref>		**In a meta-analysis from a Chinese team, more subjects receiving terazosin (vs tamsulosin) experienced dizziness and hypotension<ref>Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009 Aug;55(4):129-36. doi: 10.3109/19396360902833235. PMID: 19886768.</ref>

	==See Also==		==See Also==

Patricklin: Created page with "==Administration== Type: α-blocker Dosage Forms: CAP: 1 mg, 2 mg, 5 mg, 10 mg Routes of Administration: Oral Common Trade Names: Hytrin ==Adult Dosing== ===Benign prostatic hyperplasia=== 1-10 mg PO qhs ===Hypertension=== 1-10 mg PO qhs ===Urolithiasis=== Off-label: 2-5 mg PO qhs ==Pediatric Dosing== ''Safety/efficacy not established'' ==Special Populations== Pregnancy Rating: C. weigh risk/benefit during pregnancy; n..."

2023-10-01T03:14:49Z

Created page with "==Administration== *Type: α-blocker *Dosage Forms: CAP: 1 mg, 2 mg, 5 mg, 10 mg *Routes of Administration: Oral *Common Trade Names: Hytrin ==Adult Dosing== ===Benign prostatic hyperplasia=== *1-10 mg PO qhs ===Hypertension=== *1-10 mg PO qhs ===Urolithiasis=== *Off-label: 2-5 mg PO qhs ==Pediatric Dosing== ''Safety/efficacy not established'' ==Special Populations== *Pregnancy Rating: C. weigh risk/benefit during pregnancy; n..."

New page

==Administration==
*Type: α-blocker
*Dosage Forms: CAP: 1 mg, 2 mg, 5 mg, 10 mg
*Routes of Administration: Oral
*Common Trade Names: Hytrin

==Adult Dosing==
===[[Benign prostatic hyperplasia]]===
*1-10 mg PO qhs
===[[Hypertension]]===
*1-10 mg PO qhs
===[[Urolithiasis]]===
*Off-label: 2-5 mg PO qhs

==Pediatric Dosing==
''Safety/efficacy not established''

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C. weigh risk/benefit during pregnancy; no human data available
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out; weigh risk/benefit while breastfeeding

===Renal Dosing===
*Adult: No adjustment

===Hepatic Dosing===
*Adult: No adjustment

==Contraindications==
*Allergy to drug/class

==Adverse Reactions==
===Serious===
*Hypotension
*Syncope
*[[Priapism]]
===Common===
*Orthostatic hypotension
*Dizziness
*Headache
*Weakness
*Nausea
*Nasal Congestion

==Pharmacology==
*Half-life: 12-14 hrs
*Metabolism: CYP450
*Excretion: Feces (60%) and renal (40%)

==Mechanism of Action==
*α-1A antagonist → smooth muscle relaxation in bladder neck, prostate, urethra → increased urine flow rate (See [[Tamsulosin]])
*Theoretically less specific for bladder a-1 receptors and thus has a higher risk for orthostatic hypotension (and treats hypertension better as well)
**In a single-center European RCT, terazosin appears to be associated with a higher rate of symptomatic orthostatic hypotension<ref>de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33(5):481-8. doi: 10.1159/000019639. PMID: 9643668.</ref>
**In a meta-analysis from a Chinese team, more subjects receiving terazosin experienced dizziness and hypotension<ref>Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009 Aug;55(4):129-36. doi: 10.3109/19396360902833235. PMID: 19886768.</ref>

==See Also==
*[[Alpha blockers]]
*[[Tamsulosin]]

==References==
<references/>

[[Category:Pharmacology]]
[[Category:Urology]]

Terazosin - Revision history

Patricklin at 03:21, 1 October 2023